You are here: Industry Insights > Pfizer

News List

EMA recommends Pfizer-BioNTech’s Covid-19 vaccine for children Pharmaceutical-Technology
November 29, 2021
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion on the use of Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, in children aged five to 12 years.
COVID Protection Wanes After 2 Doses of Pfizer Vaccine: Study Drugs
November 26, 2021
Protection can gradually fade after a second dose of the COVID-19 vaccine by Pfizer-BioNTech, which suggests that a booster shot might be necessary, researchers report.
Pfizer, BioNTech Booster Gets EUA in 18 and Older ContractPharma
November 25, 2021
The U.S. FDA has expanded the emergency use authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to include individuals 18 years and older.
New Data From Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 -15 AmericanPharmaceuticalReview
November 23, 2021
Pfizer Inc. and BioNTech SE announced topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in individuals 12 through 15 years of age.
Pfizer and BioNTech receive expanded U.S. FDA emergency use suthorization of COVID-19 vaccine booster to include individuals 18 and older WorldPharmaNews
November 23, 2021
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine...
Pfizer Says Its COVID Vaccine Provides Full Protection to Adolescents Drugs
November 23, 2021
Pfizer Inc. said Monday that its coronavirus vaccine provides long-term protection in youth ages 12-15, according to data from a company clinical trial that included more than 2,200 participants.
Pfizer to supply ten million courses of Covid-19 oral antiviral to the US Pharmaceutical-Technology
November 22, 2021
The US Government has signed an agreement with Pfizer to procure ten million courses of the company’s Covid-19 oral antiviral candidate, Paxlovid (PF-07321332; ritonavir)...
Pfizer to provide U.S. government with 10 million treatment courses of investigational oral antiviral candidate to help combat COVID-19 WorldPharmaNews
November 19, 2021
Pfizer Inc. (NYSE: PFE) today announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candidate, PAXLOVID™ (PF-07321332; ritonavir)...
Pfizer and MPP to expand COVID-19 oral antiviral treatment access EuropeanPharmaceuticalReview
November 18, 2021
Pfizer and the Medicines Patent Pool (MPP), a United Nations (UN)-backed public health organisation, have announced the signing of a voluntary license agreement for Pfizer’s COVID-19 oral antiviral treatment...
Pfizer seeks FDA EUA for oral antiviral pill to treat Covid-19 Pharmaceutical-Technology
November 18, 2021
Pfizer has sought Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its experimental oral antiviral pill, Paxlovid (PF-07321332; ritonavir), to treat individuals with mild-to-moderate Covid-19.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 83 84 Next page